Skip to main content
Figure 6 | Journal of Translational Medicine

Figure 6

From: CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

Figure 6

Cell lines with acquired cisplatin resistance become more sensitive to CCI-779 whereas acquired cetuximab resistance leads to decreased sensitivity to CCI-779. The sensitivity of cisplatin-resistant cells (upper panels, dashed lines) is increased when compared to their parental counterparts (upper panels, solid lines). In contrast, cetuximab-resistant cells (lower panels, dashed lines) when compared to the parental cells (lower panels, solid lines) remain resistant to CCI-779 (UM-SCC-22BCET-R) or become more resistant to the drug (UT-SCC-9CET-R). The survival fractions shown were evaluated with long-term MTT assays and calculated on the basis of the survival of non-treated cells.

Back to article page